Healthcare
Virpax Pharmaceuticals, Inc.(VRPX)
Live Price
Offline$0.0111
+0.00% today
1Y Change
-96.02%
Window
Jun 23, 2025 โ Jun 19, 2026
- Market Cap
- โ
- Revenue Growth
- 0.0%
- EPS Growth
- -446.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 23, 2025 โ Jun 19, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Virpax Pharmaceuticals, Inc. (VRPX) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and down 96.0% across the available one-year price window (Jun 23, 2025 โ Jun 19, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -446.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -446.7%, free cash flow -169509.2% with operating margin 0.0% and ROIC 1322.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VRPX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 12, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at 0.0% and EPS is at -446.7%, with operating margin around 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -59.8% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 12, 2026 | โ | +0.0% | -96.4% | -95.5% |
2026 Mar 24, 2026 | โ | -99.1% | -96.4% | +0.0% |
2025 May 12, 2025 | โ | +64.9% | +13.3% | -96.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRPX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRPX Max Drawdown
-99.98%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRPX and SPY.
Company Overview
Virpax Pharmaceuticals, Inc.
Other OTC
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and VRP324, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
- Leadership
- Jatinder Dhaliwal
- IPO Date
- Feb 17, 2021
- Employees
- 2
- Street Address
- 1055 Westlakes Drive
- Mailing
- Berwyn, PA, 19312
- Region
- Berwyn, PA, US
- Reporting Currency
- USD
- Investor Line
- 610 727 4597
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 0.1
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- -446.7%
- Free Cash Flow
- -169509.2%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -2364.8%
- ROIC
- 1322.0%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.63
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.